ProPSA is an early marker for prostate cancer aggressiveness

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 70-74

  Heidegger, I ^a   Klocker, H ^a   Steiner, E ^a   Skradski, V ^a   Ladurner, M ^a   Pichler, R ^a   Schafer G ^b   Horninger, W ^a   Bektic, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

2 proPSA; cancer aggressiveness; Gleason score; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD; CANCER GRADING; DISEASE COURSE; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; HUMAN; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

ADULT; AGED; AREA UNDER CURVE; DISEASE PROGRESSION; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894075454     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.50     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp 2011;35:501-514.
3. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381.
4. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001;166:845-850.
5. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999;54:220-224.
6. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-2439.
7. Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010;7:487-493.
8. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2012;112:717-728.
9. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001;38(Pt 6):633-651.
10. Djavan B. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium. Eur Urol 2010;57:928-929.
11. Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003;62:177-181.
12. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170(6 Pt 1):2181-2185.
13. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171(6 Pt 1):2239-2244.
14. Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS et al. Seminal plasma contains "BPSA", a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000;45:271-276.
15. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 2003;61:274-276.
16. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-1200.
17. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-927.
18. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG et al. Prospective, Multi-Center Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. J Urol 2012;189:867-870.
19. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
20. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer, 1997;80:1818-1829.
21. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809-816.
22. Laffin RJ, Chan DW, Tanasijevic MJ, Fischer GA, Markus W, Miller J et al. Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. Clin Chem 2001;47:129-132.
23. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-6963.
24. Finlay JA, Day JR, Evans CL, Carlson R, Kuus-Reichel K, Millar LS et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 2001;47:1218-1224.
25. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur Urol 2012;61:652-661.
26. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007;43:1918-1926.
27. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69:198-207.
28. Lazzeri M, Haese A, de la TA, Palou RJ, McNicholas T, Lughezzani G et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013;63:986-994.
29. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012;4:127rv3.
30. Pelzer AE, Colleselli D, Bektic J, Steiner E, Ramoner R, Mitterberger M et al. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference? BJU Int 2008;101:822-825